Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert

Journal of Neurochemistry

Volumn 99, Issue 6, 2006, Pages 1445-1455

  Engel, Tobias ^a   Goñi Oliver, Paloma ^a   Lucas, José J ^a   Avila, Jesús ^a   Hernández, Félix ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer's disease; Frontotemporal dementia and parkinsonim linked to chromosome 17; Glycogen synthase kinase 3; Lithium; Neurofibrillary tangles

Indexed keywords

DOXYCYCLINE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 17; CONTROLLED STUDY; ENZYME INHIBITION; FRONTOTEMPORAL DEMENTIA; GENE OVEREXPRESSION; HIPPOCAMPUS; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENIC MOUSE;

AGE FACTORS; ANIMALS; ATROPHY; BLOTTING, WESTERN; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; LITHIUM; MICE; MICE, TRANSGENIC; MICROSCOPY, IMMUNOELECTRON; MICROTUBULE-ASSOCIATED PROTEINS; NEUROFIBRILLARY TANGLES; NEURONS; NUCLEAR PROTEINS; ORGANIC CHEMICALS; PHOSPHORYLATION; TAU PROTEINS;

ANIMALIA;

EID: 33845530335     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04139.x     Document Type: Article

References (45)

1. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I. and Iqbal K. (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl Acad. Sci. USA 98, 6923-6928.
2. Alvarez G., MunozMontano J. R., Satrustegui J., Avila J., Bogonez E. and DiazNido J. (1999) Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 453, 260-264.
3. Arrasate M., Mitra S., Schweitzer E. S., Segal M. R. and Finkbeiner S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810.
4. Avila J., Lucas J. J., Perez M. and Hernandez F. (2004) Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384.
5. Bhat R. V., Budd Haeberlein S. L. and Avila J. (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89, 1313-1317.
6. Biernat J., Mandelkow E. M., Schroter C. et al. (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 11, 1593-1597.
7. Bizon J. L. and Gallagher M. (2003) Production of new cells in the rat dentate gyrus over the lifespan: relation to cognitive decline. Eur. J. Neurosci. 18, 215-219.
8. Busciglio J., Lorenzo A., Yeh J. and Yankner B. A. (1995) beta-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888.
9. Chen G., Du Rajkowska G. F., Seraji-Bozorgzad N. and Manji H. K. (2000) Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75, 1729-1734.
10. Chen R. W. and Chuang D. M. (1999) Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274, 6039-6042.
11. Engel T., Hernandez F., Avila J. and Lucas J. J. (2006a) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090.
12. Engel T., Lucas J. J., Gomez-Ramos P., Moran M. A., Avila J. and Hernandez F. (2006b) Coexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 27, 1258-1268.
13. Ferreira A., Lu Q., Orecchio L. and Kosik K. S. (1997) Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell Neurosci. 9, 220-234.
14. Goedert M. (2005) Tau gene mutations and their effects. Mov. Disord. 20, S45-S52.
15. Goedert M. and Spillantini M. G. (2001) Tau gene mutations and neurodegeneration. Biochem. Soc. Symp. 67, 59-71.
16. Greenberg S. G. and Davies P. (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl Acad. Sci. USA 87, 5827-5831.
17. Grimes C. A. and Jope R. S. (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65, 391-426.
18. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y. C., Zaidi M. S. and Wisniewski H. M. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089.
19. Hernandez F., Borrell J., Guaza C., Avila J. and Lucas J. J. (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 83, 1529-1533.
20. Hong M., Chen D. C. R., Klein P. S. and Lee V. M. Y. (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272, 25 326-25 332.
21. Imahori K. and Uchida T. (1997) Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. (Tokyo) 121, 179-188.
22. Kempermann G., Kuhn H. G. and Gage F. H. (1998) Experience-induced neurogenesis in the senescent dentate gyrus. J. Neurosci. 18, 3206-3212.
23. King T. D., Bijur G. N. and Jope R. S. (2001) Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 919, 106-114.
24. Klein P. S. and Melton D. A. (1996) A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA 93, 8455-8459.
25. Kosik K. S. (1992) Alzheimer's disease: a cell biological perspective. Science 256, 780-783.
26. Lim F., Hernandez F., Lucas J. J., Gomez-Ramos P., Moran M. A. and Avila J. (2001) FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell Neurosci. 18, 702-714.
27. Lovestone S., Hartley C. L., Pearce J. and Anderton B. H. (1996) Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience 73, 1145-1157.
28. Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R. and Avila J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
29. Mena R., Edwards P., Perez-Olvera O. and Wischik C. M. (1995) Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease. Acta Neuropathol. 89, 50-56.
30. Merrick S. E., Demoise D. C. and Lee V. M. Y. (1996) Site-specific dephosphorylation of tau protein at Ser(202)/Thr(205) in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. J. Biol. Chem. 271, 5589-5594.
31. Moore G. J., Bebchuk J. M., Wilds I. B., Chen G. and Manji H. K. (2000) Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242.
32. MunozMontano J. R., Moreno F. J., Avila J. and DiazNido J. (1997) Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411, 183-188.
33. MunozMontano J. R., Moreno F. J., Avila J. and DiazNido J. (1999) Downregulation of glycogen synthase kinase-3 beta (GSK-3 beta) protein expression during neuroblastoma IMR-32 cell differentiation. J. Neurosci. Res. 55, 278-285.
34. Nakashima H., Ishihara T., Suguimoto P. et al. (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. (Berl.) 110, 547-556.
35. Noble W., Planel E., Zehr C. et al. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990-6995.
36. Paxinos G. and Franklin K. B. J. (2001) The Mouse Brain, 2nd edn. Academic Press, San Diego.
37. Pei J. J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B. and Cowburn R. F. (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019.
38. Perez M., Valpuesta J. M., Montejo de Garcini E., Quintana C., Arrasate M., LopezCarrascosa J. L., Rabano A., deYebenes J. G. and Avila J. (1998) Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am. J. Pathol. 152, 1531-1539.
39. Perez M., Hernandez F., Lim F., Diaz-Nido J. and Avila J. (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 5, 301-308.
40. Santacruz K., Lewis J., Spires T. et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
41. Takashima A., Noguchi K., Sato K., Hoshino T. and Imahori K. (1993) Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl Acad. Sci. USA 90, 7789-7793.
42. Takashima A., Noguchi K., Michel G., Mercken M., Hoshi M., Ishiguro K. and Imahori K. (1996) Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I glycogen synthase kinase-3 beta. Neurosci. Lett. 203, 33-36.
43. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C. A. and Imahori K. (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. (Berl.) 92, 232-241.
44. Yu I. T., Kim J. S., Lee S. H., Lee Y. S. and Son H. (2003) Chronic lithium enhances hippocampal long-term potentiation, but not neurogenesis, in the aged rat dentate gyrus. Biochem. Biophys. Res. Commun. 303, 1193-1198.
45. Zhang F., Phiel C. J., Spece L., Gurvich N. and Klein P. S. (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278, 33 067-33 077.